OOIR: Observatory of International Research

Papers

(The median citation count of Hematological Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Cutaneous T‐cell lymphomas—An update 2021	38
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis	33
Langerhans cell histiocytosis: Version 2021	30
Bispecific antibodies for the treatment of lymphomas: Promises and challenges	26
Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B‐cell lymphoma	24
Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019	22
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas	22
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma	21
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials	20
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience	19
Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies	18
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS	18
Hsa_circ_0002483 regulates miR‐758‐3p/MYC axis to promote acute myeloid leukemia progression	18
Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource‐constrained setting	17
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY	17
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations	17
Immunohistochemistry for c‐myc and bcl‐2 overexpression improves risk stratification in primary central nervous system lymphoma	16
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL	16
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients	16
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study	16
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature	15
Obinutuzumab‐related adverse events: A systematic review and meta‐analysis	15
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data	15
Immunomodulatory treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)	15
Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome	14

Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/	14
Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide	14
Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity	14
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemic	13
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis	13
Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR‐625‐5p/SOX12 axis	13
The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors	13
Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels	12
THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS	12
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma	12
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study	12
Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma	12
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL	12
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐	12
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia	11
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma pat	11
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort	11
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection	11
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma	11
Optimizing CAR T cell therapy in lymphoma	10
Bendamustine‐rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients	10
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy	10
The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER‐based analysis	10
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia	10
On point in primary CNS lymphoma	10
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study	10
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant	10
FAM213A is linked to prognostic significance in acute myeloid leukemia through regulation of oxidative stress and myelopoiesis	10
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY	10
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience	9
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience	9
Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and	9
Prognostic significance of histologic grade and Ki‐67 proliferation index in follicular lymphoma	9
Salvage therapy with “Dara‐KDT‐P(A)CE” in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma	9
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3	9
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients	9
Direct oral anticoagulants in patients with hematologic malignancies	8
KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88^MT LYMPHOMA MODELS	8
Allogeneic stem cell transplant in non‐Hodgkin lymphomas: Still an indication?	8
The role of long non‐coding RNAs and downstream signaling pathways in leukemia progression	8
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report	8
Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy	8
Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T‐cell leukemia/lymphoma	8
IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL	8
Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis	8
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a	8
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection	8
Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1	8
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedull	8
Prognostic significance of IKZF1 deletions and IKZF1^plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocol	8

Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma	7
Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients	7
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group	7
FZD6 triggers Wnt–signalling driven by WNT10B^IVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia	7
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real‐life experience	7
Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation	7
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma	7
Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma	7
Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia	7
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY	7
Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials	7
Clinical trial risk in leukemia: Biomarkers and trial design	7
Combining T‐cell‐based immunotherapy with venetoclax elicits synergistic cytotoxicity to B‐cell lines in vitro	7
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	7
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma	7
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches	7
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY	7
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL	7
Clinical potential of introducing next‐generation sequencing in patients at relapse of acute myeloid leukemia	7
Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis	7
Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <	7
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients	7
Safe and effective treatment of follicular lymphoma in patients with HCV‐infection	6
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemia	6
Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation	6
Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis	6
Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphoma	6
Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus‐infected patients	6
Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial	6
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL	6
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES	6
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type	6
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	6
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients	6
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis	6
Extended follow‐up of CD4⁺ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine	6
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS	6
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations	6
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of contr	6
CAR T‐cell therapy in large B cell lymphoma	6
Sequencing of myeloma therapy: Finding the right path among many standards	6
CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia	6
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort	6
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era	6
SINTILIMAB PLUS CHIDAMIDE FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM, PHASE IB/II TRIAL (SCENT)	6
BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL	6
Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation	6
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY	6
Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study	6
Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors	5
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES	5
Association of Epstein–Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency‐associated lymphoproliferative disorders in pati	5
Molecular classification of aggressive lymphomas—past, present, future	5
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents	5
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA	5
CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECT	5
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826	5
The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases	5
Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogen	5
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression	5
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK	5
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor‐based regimens as induction tre	5
Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group	5
Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B‐cell lymphoma	5
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study	5
NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma	5
The evolving therapy of DLBCL: Bispecific antibodies	5
Genetics and epigenetics of leukemia and lymphoma: from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute	5
Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis	5
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with rela	5
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controll	5
Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper	5
High‐grade B‐cell lymphomas with MYC and BCL2 translocations lack tumor‐associated macrophages and PD‐L1 expression: A possible noninflamed subgroup	5
Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma	5
Salvage therapy with decitabine in combination with granulocyte colony‐stimulating factor, low‐dose cytarabine, and aclarubicin in patients with refractory or relapsed early T‐cell precursor acute lym	5
TNF‐α increases the risk of bleeding in patients after CAR T‐cell therapy: A bleeding model based on a real‐world study of Chinese CAR T Working Party	5
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC	5
The “m6A writer” METTL3 and the “m6A reader” IGF2BP2 regulate cutaneous T‐cell lymphomas progression via CDKN2A	5
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	5
High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma	5

Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group	5
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma	5
Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemia	5
Critical role of the high mobility group A proteins in hematological malignancies	5
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY	4
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leu	4
Primary large B‐cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH‐CCND1): Diffuse large B‐cell lymphoma with CCND1	4
ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT	4
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation	4
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma	4
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant	4
Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib	4
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia	4
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)	4
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	4
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells	4
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controll	4
High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines	4
Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients	4
TAFRO syndrome: A disease that known is half cured	4
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome	4
UPDATED EFFICACY AND SAFETY RESULTS OF ORELABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LEUKEMIA	4
Prognostic impact of B‐vitamins involved in one‐carbon metabolism in patients with diffuse large B‐cell lymphoma	4
Clinical significance of tryptophan catabolism in follicular lymphoma	4
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy	4
OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY	4
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches	4
Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies	4
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia	4
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms	4
Precision medicine in follicular lymphoma: Focus on predictive biomarkers	4
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY	4
Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysis	4
What's new in peripheral T‐cell lymphomas	4
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)	4
Is race important in genomic classification of hematological neoplasms?	4
Hypercalcemia at diagnosis of diffuse large B‐cell lymphoma is not uncommon and is associated with high‐risk features and a short diagnosis‐to‐treatment interval	4
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY	4
Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma	4
Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: A single‐institution experience on 1247 installations in 94 consecutive patien	4
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics	4
High‐risk follicular lymphoma: Treatment options	4
Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphoma	4
Cellular therapy in lymphoma	4
Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia	4
PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417	4
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis	4
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis	4
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort study	4
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis	4
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies	4
The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia‐related changes treated with azaciti	4
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy	4
FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPY	4
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia	4
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review	4
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management	4
Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement	4
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION	4
Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis	4
In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions	4
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)	4
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone	4
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era	3
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY	3
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospec	3
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6	3
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FI	3
Reimagining diversity in multiple myeloma clinical trials	3
Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies	3
The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi	3
Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies	3
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents	3
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system	3
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)	3
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA	3
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation	3
Are we reaching the maximum cure rate for Hodgkin lymphoma?	3
Novel agents in relapsed/refractory diffuse large B‐cell lymphoma	3
Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia	3
Clinical significance of MYD88 non‐L265P mutations in diffuse large B‐cell lymphoma	3
LncRNA FIRRE stimulates PTBP1‐induced Smurf2 decay, stabilizes B‐cell receptor, and promotes the development of diffuse large B‐cell lymphoma	3
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY	3
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myel	3
Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas	3
Drug cost savings in phase III hematological oncology clinical trials in a university hospital	3
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	3
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	3
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)	3
B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma	3
EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1	3
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B‐cell lymphoma and treated with anthracyclines	3
Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition	3
PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA	3
CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment	3